Clinical trials
3 active studies led by LB Pharmaceuticals Inc., of 6 in all
Source: ClinicalTrials.gov, Studies with LB Pharmaceuticals Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 1Markets in public records
- 0Regions & countries
- 3Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by LB Pharmaceuticals Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on LB Pharmaceuticals Inc.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Company facts
- Stock listing
- NASDAQ: LBRX
- Type
- Medicines
Source: SEC EDGAR, Company filings, CIK 1691082. Retrieved 13 Nov 2026.
See them on ClinicalTrials.gov (opens in a new tab)
SEC filings
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1691082.
Trials over time
Studies LB Pharmaceuticals Inc. leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with LB Pharmaceuticals Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show LB Pharmaceuticals Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets LB Pharmaceuticals Inc. is in.
From our blog
Stories on the topics LB Pharmaceuticals Inc. works in.
Adaptogens: Ancient Herbs, Modern Market
170 WHO Member States report the use of traditional medicine. Adaptogens like ashwagandha, rhodiola and…
Read
Stress and Mood Supplements: Ashwagandha and Beyond
Depression and anxiety cost the world about US$1 trillion a year. Ashwagandha has some evidence for stress…
Read
Antidepressants: Demand, Access and New Approaches
About 322 million people live with depression. Treatment works, but most people still do not get it.
ReadSearch all reports for LB Pharmaceuticals Inc. All companies